Oncofid-P-B is under clinical development by Fidia farmaceutici and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Oncofid-P-B’s likelihood of approval (LoA) and phase transition for Bladder Carcinoma took place on 02 Sep 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Oncofid-P-B Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Oncofid-P-B overview

Paclitaxel-hyaluronan (Oncofid-P-B) is under development for the treatment of non-muscle invasive bladder cancer, papillary cancer and malignant mesothelioma. The drug candidate consists of paclitaxel combined with hyaluronan as a bioconjugate.The drug candidate is administered by intravesicular route as a solution and acts by targeting tubulin.

Fidia farmaceutici overview

Fidia farmaceutici (Fidia), a subsidiary of P&R SpA, is a healthcare products provider that specializes in research, development and manufacturing of hyaluronic acid-based products. The company develops and commercializes products for specific therapeutic areas which include joint health care with primary emphasis on osteoarthritis; advanced wound care; and aesthetic medicine, among others. It also provides products for other therapeutic areas such as impaired joint function; acute localized pain; herpes labialis; burns, rashes, and others. Fidia operates along with its subsidiaries located in the US, Germany and Kazakhstan. The company works in partnership with pharmaceutical and biomedical companies to commercializes its products worldwide. Fidia is headquartered in Abano Terme, Italy.

Quick View Oncofid-P-B LOA Data

Report Segments
  • Innovator
Drug Name
  • Oncofid-P-B
Administration Pathway
  • Intravesical
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.